Quantcast

Latest Chimeric antigen receptor Stories

2015-01-13 16:25:45

Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies GERMANTOWN, Md., BOSTON,

2015-01-05 08:31:49

Alliance Combines Amgen's Oncology Targets and Kite's Leading CAR T Cell Therapy Platform to Develop new Therapeutic Candidates THOUSAND OAKS, Calif.

2014-12-19 08:24:17

Developing Next Generation Cancer Immunotherapy with "Off-the-Shelf" Chimeric Antigen Receptor-Tumor Attacking Natural Killer (CAR-TNK(TM)) Cell Lines SAN DIEGO and CARDIFF-BY-THE-SEA,

2014-12-06 16:21:12

--CHOP-Led Pilot Study Engineers Patients' Own Immune Cells to Hunt Down Cancer Cells in Blood-- PHILADELPHIA, Dec.

2014-12-06 16:21:05

- Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions[1] EAST HANOVER, N.J., Dec.

2014-11-18 12:28:22

SEATTLE, Nov. 18, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, Inc.

2014-08-05 08:33:51

Total Investment Tops $300M in Less Than 12 Months SEATTLE, Aug.

2014-06-06 12:24:27

SANTA MONICA, Calif., June 6, 2014 /PRNewswire/ -- Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for


Word of the Day
alicorn
  • The horn of a unicorn considered as a medical or pharmacological ingredient.
  • A winged horse with a single horn on its head; a winged unicorn.
The word 'alicorn' comes from Italian alicorno, already associated with unicorns and reinterpreted, popularized by Bearing an Hourglass (1984) and other fantasy novels by Piers Anthony.
Related